HAVCR2 and lung carcinoma: Taking TIM3 as an example, research has revealed that the combined application of PD1 and TIM3 inhibitors significantly enhances the immune activity of effector T cells in animal models such as acute myelogenous leukemia and lung cancer, surpassing the efficacy of using PD1 inhibitors alone [10, 11].